A new class of targeted protein degradation therapeutics just got a significant boost, with Degron Therapeutics announcing it has closed its Series A funding round, securing $40.0M. The biotech firm aims to become a global leader in developing small molecule molecular glue degrader (MGD) drugs, focusing on disease targets previously considered undruggable.
The investment round drew support from LAPAM CAPITAL, GTJA Investment Group, Fortune Capital, and CSPC & Growth. Degron plans to leverage its scientific expertise to identify and validate novel selective MGD compounds, addressing unmet medical needs across all therapeutic areas.













